Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Berzosertib - Merck KGaA

Next Previous
Drug Profile

Berzosertib - Merck KGaA

Alternative Names: Captisol® enabled VX 970; M-6620; MSC 2527093A; VX-970

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer EMD Serono Research & Development Institute; Massachusetts General Hospital; Merck KGaA; National Cancer Institute (USA); University of Oxford
  • Class Amines; Antineoplastics; Isoxazoles; Pyrazines; Radiation-sensitising agents; Small molecules
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fallopian tube cancer; Gastric cancer; Leiomyosarcoma; Ovarian cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Urogenital cancer
  • No development reported Acute myeloid leukaemia; Head and neck cancer; Oesophageal cancer

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in Hungary (IV, Infusion)
  • 28 Mar 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Monotherapy, Second-line therapy or greater) in Hungary (IV, Infusion)
  • 26 Dec 2024 National Cancer Institute completes phase I/II trial in Small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT02487095)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top